Ginkgo Bioworks Holdings (DNA) AI Stock Analysis

• Market Cap: $686.13M
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.77
• Revenue Growth: 25.21%
• EPS Growth: 67.53%
• Country: US
• Employees: 834
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.45
• Shares Outstanding: 47,089,600
• 10 Day Avg. Volume: 1,135,709
• 30 Day Avg. Volume: 1,586,844
• PEG Ratio: 0.02
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 2.24
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $11.50
• Price Target Upside: 1.77% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $11.00 ▼(-2.65% Downside)

Ginkgo Bioworks Holdings faces significant challenges with profitability and cash flow, as reflected in its financial performance and valuation scores. The technical analysis indicates bearish momentum, while the earnings call provides some optimism with strategic cost reductions and a strong cash position. However, the overall outlook remains cautious due to ongoing revenue declines and operational inefficiencies.

Positive Factors

Strong Cash Position

A strong cash position with no bank debt provides Ginkgo Bioworks with financial flexibility to invest in growth opportunities and weather economic downturns.

BARDA Award

Securing a BARDA award enhances Ginkgo's credibility and financial resources, supporting innovation in biomanufacturing and strengthening its market position.

Extended Partnership with Bayer

The extended partnership with Bayer highlights Ginkgo's capability in microbial engineering, securing long-term collaboration with a major industry player.

Negative Factors

Significant Revenue Decline in Cell Engineering

A significant decline in Cell Engineering revenue indicates challenges in maintaining growth and could impact the company's overall financial performance.

Increased Cell Engineering Segment Operating Loss

Rising operating losses in the Cell Engineering segment suggest inefficiencies and could hinder Ginkgo's profitability and cash flow improvements.

Negative Adjusted EBITDA

A negative adjusted EBITDA indicates ongoing operational challenges and may limit Ginkgo's ability to reinvest in its business for future growth.

Ginkgo Bioworks Holdings Business Overview & Revenue Model

Company Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Ginkgo Bioworks generates revenue through several key streams primarily focused on its partnerships and customer contracts in the biotechnology sector. The company collaborates with various organizations, including pharmaceutical, agricultural, and industrial companies, to develop custom organisms tailored to specific needs. Revenue is generated from service fees for its organism design and development services, as well as from licensing agreements that allow partners to utilize Ginkgo's proprietary technologies. Additionally, Ginkgo may earn royalties from commercialized products developed using its engineered organisms. Significant partnerships with major corporations enhance Ginkgo’s revenue potential by providing access to larger markets and more substantial projects, contributing notably to its earnings.

Ginkgo Bioworks Holdings Financial Statement Overview

Summary

Ginkgo Bioworks Holdings shows strong gross margins but struggles with profitability and cash flow, reflecting operational inefficiencies and growth challenges. The balance sheet is relatively stable, but the company needs to address its negative cash flows and improve its return on equity to enhance financial health.

Income Statement

The company exhibits a strong gross profit margin of over 82% in TTM, indicating effective cost management. However, the net profit margin is significantly negative, reflecting substantial losses. Revenue has declined over the past year, suggesting challenges in growth. The negative EBIT and EBITDA margins further highlight operational inefficiencies.

Balance Sheet

The debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting ongoing losses and inefficiencies in generating shareholder value. The equity ratio remains stable, suggesting a solid asset base relative to equity.

Cash Flow

The company faces negative operating and free cash flows, indicating cash burn. The free cash flow to net income ratio is above 1, suggesting that cash flow losses are less severe than accounting losses. However, the negative growth in free cash flow highlights ongoing cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	230.81M	227.04M	251.46M	477.71M	313.84M	76.66M
Gross Profit	189.72M	188.49M	197.45M	273.49M	184.15M	61.05M
EBITDA	-312.44M	-484.39M	-821.29M	-2.06B	-1.81B	-108.58M
Net Income	-315.19M	-547.03M	-892.87M	-2.10B	-1.83B	-126.61M
Balance Sheet
Total Assets	1.23B	1.38B	1.67B	2.54B	2.07B	675.15M
Cash, Cash Equivalents and Short-Term Investments	473.69M	561.57M	944.07M	1.32B	1.55B	380.80M
Total Debt	428.83M	467.73M	241.77M	442.59M	23.03M	17.00M
Total Liabilities	618.06M	661.39M	568.19M	803.04M	503.61M	205.10M
Stockholders Equity	612.95M	716.06M	1.10B	1.74B	1.51B	461.38M
Cash Flow
Free Cash Flow	-274.17M	-382.13M	-336.30M	-304.47M	-310.34M	-193.65M
Operating Cash Flow	-237.71M	-319.58M	-295.50M	-252.20M	-253.82M	-135.83M
Investing Cash Flow	-285.86M	-62.24M	-80.69M	-67.39M	-73.26M	-67.12M
Financing Cash Flow	-973.00K	-1.74M	-3.22M	95.34M	1.53B	90.32M

Ginkgo Bioworks Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNA, the sentiment is Negative. The current price of 11.3 is below the 20-day moving average (MA) of 13.09, below the 50-day MA of 12.67, and above the 200-day MA of 10.45, indicating a neutral trend. The MACD of -0.43 indicates Positive momentum. The RSI at 39.95 is Neutral, neither overbought nor oversold. The STOCH value of 9.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DNA.

Ginkgo Bioworks Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$1.46B	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DNA	46 Neutral	$686.13M	―	-43.59%	―	25.21%	67.53%
TRML	45 Neutral	―	―	-29.62%	―	―	6.66%
RAPP	44 Neutral	$1.21B	―	-29.42%	―	―	―
ERAS	34 Underperform	$624.07M	―	-31.16%	―	―	50.77%
SANA	33 Underperform	$1.06B	―	-109.12%	―	―	7.58%

Ginkgo Bioworks Holdings Corporate Events

Ginkgo Bioworks Reports Q3 2025 Financial Results

Ginkgo Bioworks Holdings, Inc. is a biotechnology company specializing in the development of tools and technologies to make biology easier to engineer, focusing on sectors such as therapeutics, diagnostics, and manufacturing. The company also offers biosecurity solutions to address biological threats.

Ginkgo Bioworks Enters Sales Agreement for Stock Offering

On September 4, 2025, Ginkgo Bioworks Holdings entered into a Sales Agreement with Allen & Company LLC to potentially sell up to $100 million of its Class A common stock in at-the-market offerings. The proceeds from these sales, if any, are intended for general corporate purposes, including financing operations and technology development. The agreement allows flexibility in selling shares and includes customary rights and termination options for both parties. This move could impact the company’s market positioning by providing additional capital to support its growth and operations in the competitive synthetic biology industry.

The most recent analyst rating on (DNA) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Ginkgo Bioworks Settles Stockholder Derivative Actions

On May 27, 2025, Ginkgo Bioworks Holdings reached a Stipulation and Agreement of Settlement to resolve stockholder derivative actions against certain individuals. The settlement, preliminarily approved by the court on August 21, 2025, includes a $4,125,000 insurance-funded payment, corporate governance reforms, and the dismissal of the actions. A final hearing is set for December 18, 2025.

The most recent analyst rating on (DNA) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.

Ginkgo Bioworks Earnings Call: Mixed Sentiment and Strategic Growth

Ginkgo Bioworks Holdings, Inc. recently held its earnings call, revealing a mixed sentiment. The company highlighted significant achievements in cost reduction and financial metrics, alongside successful product launches. However, challenges persist with lowered revenue guidance in the biosecurity segment and ongoing operating losses. Despite these hurdles, Ginkgo is strategically positioned for future growth, particularly in automation and life science tools.

Ginkgo Bioworks Reports Q2 2025 Financial Results

Ginkgo Bioworks Holdings, Inc. is a company that specializes in cell programming and biosecurity, providing tools for engineering biology and offering services across therapeutics, diagnostics, and manufacturing. In its latest earnings report for the second quarter of 2025, Ginkgo Bioworks announced a total revenue of $50 million, a slight decrease from the previous year. The company reported an 8% increase in cell engineering revenue, driven by demand from biopharma and government sectors, while biosecurity revenue saw a decline. Despite a net loss of $60 million, the company improved its adjusted EBITDA to a loss of $28 million, a significant improvement from the previous year, due to reduced operating expenses. Ginkgo Bioworks highlighted its strategic advancements, including the launch of new services and products, and the achievement of a $250 million cost-saving target ahead of schedule. The company continues to focus on expanding its automation and data capabilities, securing major contracts, and enhancing its service offerings. Looking ahead, Ginkgo Bioworks maintains its revenue outlook for 2025 and aims to reach adjusted EBITDA breakeven by the end of 2026, reflecting confidence in its strategic direction and financial discipline.